Zadaxin

[Guest guest]

This was one of the few articles that mentioned C as well as B.

" SciClone Will Position ZADAXIN for Hepatitis B, Hepatitis C and

Cancer "

SAN MATEO, Calif., March 26 /CNW/ -- SciClone Pharmaceuticals

(Nasdaq: SCLN) today reported that ZADAXIN® thymosin alpha 1, the

Company's lead product, has been approved in Pakistan. SciClone will

position ZADAXIN for the treatment of hepatitis B, hepatitis C and

multiple types of cancer, including hepatocellular carcinoma, the most

common type of primary liver cancer.

" Pakistan is an important Asian market, " said R. Sellers,

SciClone's President and Chief Executive Officer. " We expect to begin

selling ZADAXIN to Pakistan early next quarter. "

ZADAXIN now is approved for marketing in 13 countries: Argentina,

Cambodia, the People's Republic of China, Italy, Kuwait, Mexico,

Myanmar, Peru, Pakistan, the Philippines, Singapore, Venezuela and

Vietnam. SciClone has filed for approval to market ZADAXIN in 19

additional countries.

Phase 3 studies of ZADAXIN in hepatitis B and Phase 2 studies in

hepatitis C are being conducted in Japan by Schering-Plough K.K.,

SciClone's exclusive partner in that market.

Hepatitis B and hepatitis C are highly infectious liver diseases

that can lead to liver cancer and death. Worldwide, there are

approximately 350 million long term carriers of the hepatitis B virus

and an estimated

170 million carriers of the hepatitis C virus.

Primary liver cancer is the most common cancer in the world.

Hepatocellular carcinoma is the most common type of primary liver

cancer. Although in the U.S. primary liver cancer accounts for less

than 1% of all

cancers, in territories such as Asia it accounts for up to 50% of

cancer cases. Chronic carriers of the hepatitis B or hepatitis C virus

are at substantially increased risk to develop hepatocellular

carcinoma.

SciClone Pharmaceuticals is a global biopharmaceutical company that

acquires, develops and commercializes specialist-oriented drugs for

treating

chronic and life-threatening diseases, such as hepatitis B, hepatitis

C, cystic fibrosis, cancer and immune system disorders. Press releases

and corporate information from SciClone Pharmaceuticals are available

on the Internet at www.sciclone.com or by calling the Company's

Investor Relations Department at 800-724-2566. SciClone's common stock

is listed on The Nasdaq National Market® under the symbol SCLN.

For further information: K. Singh, Senior Vice President of

SciClone Pharmaceuticals, 650-358-1451/

/Web site: http://www.sciclone.com

===

Visit my webpage for parents of troubled teens at:

http://members.tripod.com/~rdhd45vlcek/index.html

and my support group for those parents at:

http://clubs./clubs/parentingtroubledteens

ICQ 22539187

_____________________________________________________________